Analyst Research

Report Title Price
Provider: Thomson Reuters Stock Report
$25.00
Provider: Reuters Investment Profile
$20.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

4d Pharma PLC receives orphan drug designation for Rosburix


Thursday, 7 Aug 2014 02:01am EDT 

4d Pharma PLC:Says the U.S. Food and Drug Administration (FDA) has granted orphan drug designation for Rosburix, for the treatment of ulcerative colitis in paediatric patients (PUC).Rosburix is 4D's second live biotherapeutic to receive orphan designation, having received orphan designation from the FDA for the treatment of paediatric Crohns with Thetanix in Sept. 2013.